🗳️ What This Document Is

This document is a Definitive Proxy Statement (DEF 14A) for Absci Corp’s 2026 Annual Meeting of Stockholders. Simply put, this is a massive, formal letter from the company to its shareholders that details not only the important operational updates (like new drug progress) but also the mechanical rules governing the meeting itself. Investors need to read this to understand what they are voting on and how they can exercise their rights as stockholders.

👉 Why it matters: The document serves two masters: providing an optimistic, forward-looking view of the company's pipeline (via the CEO’s letter) and providing a highly detailed, required legal playbook on corporate governance (the voting rules and board structure).

🔬 Absci's Science and Strategic Direction

The CEO, Sean McClain, laid out the company's core strategy: using generative AI to develop better biologics for conditions with high unmet needs. Absci aims to move from the "code" (AI development) to the "clinic" (patient trials). The core philosophy is building the company's own pipeline using a proprietary tool called Origin-1.

• Core Strategy: Absci is a clinical-stage biotech company focused on using generative AI to create new biologics. They are emphasizing "Origin-1," which is the latest AI model for designing full-length antibodies against "zero-prior" epitopes—meaning they target scientific sites that haven't been studied before.
  • Why it matters: This approach signals that Absci is building a unique, internal engine (Origin-1) to overcome historical challenges in drug development, rather than just focusing on licensing existing targets.
• External Validation: The company highlighted its value to partners, noting that its 2025 partnership with Almirall was successful, even expanding to include a second dermatology target.
  • Why it matters: Successful partnerships validate the platform's value to outside companies, providing third-party confirmation of its technical strength.

💉 Clinical Progress: The ABS-201 Program

The star of Absci’s current development is ABS-201, an AI-designed anti-PRLR antibody. The CEO’s letter provided detailed updates on two major indications: Androgenetic Alopecia (A.A.) and Endometriosis.

For Androgenetic Alopecia (A.A.):

• Timeline/Efficiency: The team brought ABS-201 from discovery to the clinic in roughly 2 years at an estimated cost of $15 million. The CEO noted this is significantly faster and cheaper than the industry average of 4–6 years and over $50 million.
• Key Data Points:
  • In human ex-vivo scalp models, ABS-201 was shown to stimulate hair growth and protect and expand the stem cell niche.
  • In preclinical primate models, a single treatment course maintained hair regrowth for up to 4 years without continuous dosing.
• Upcoming Milestones: Absci expects clinical proof-of-concept data from the HEADLINE trial in the second half of 2026.

For Endometriosis:

• Mechanism: The company is targeting the "prolactin stress axis," which is implicated in both hair miniaturization and endometriosis. The treatment aims to be non-hormonal.
• Clinical Goal: Unlike treatments that merely mask symptoms, ABS-201 in this area aims for potential disease-modifying treatment for a condition affecting roughly 1 in 10 women worldwide.
• Timeline: They are targeting Phase 2 initiation in Q4 2026, with proof-of-concept data anticipated in the second half of 2027.

📅 The Annual Meeting and Logistics

The annual meeting is the formal setting where shareholders exercise their voting power and hear updates. The meeting is scheduled for Thursday, June 4, 2026, at 9:00 a.m. Eastern Time and will be held virtually.

• Voting Process: Shareholders must pre-register at www.virtualshareholdermeeting.com/ABSI2026 using a 16-digit control number.
• Voting Methods: Shareholders can vote by Internet (www.proxyvote.com), during the Annual Meeting, by telephone (1-800-690-6903), or by mail.
• Record Date: The record date for determining who is entitled to vote is the close of business on April 7, 2026.

🏛️ Board Structure and Leadership

The board is composed of a mix of founders, internal management, and highly experienced external directors. The governance structure is designed to separate key roles, which is viewed as a sign of strong corporate oversight.

• Leadership Separation: Mr. van Houten has been the Board Chair since April 2024, and Mr. McClain remains the CEO. Separating these roles allows the CEO to focus on strategy while the Chair leads the board's oversight.
• Director Terms: The board is organized into three classes (I, II, and III), with terms expiring in different years:
  • Class I: Frans van Houten (expires 2028) and Karen McGinnis (expires 2028).
  • Class II: Prof Sir Menelas Pangalos, Ph.D. and Daniel Rabinovitsj (expires at the 2026 meeting).
  • Class III: Sean McClain (expires 2027), Joseph Sirosh, Ph.D. (expires 2027), and Mary Szela (expires 2027).
• Director Expertise: The board includes major industry veterans, such as Prof Sir Menelas Pangalos, Ph.D., who has served at institutions like AstraZeneca and Pfizer, and Mary Szela, who has experience as CEO at firms like Aegerion Pharmaceuticals.

📜 Governance and Voting Mechanics

This section details the rules of corporate governance, which govern how decisions are made and how the board operates.

• Proposal 1 (Director Election): Shareholders vote to elect two Class II directors: Prof Sir Menelas Pangalos, Ph.D. and Daniel Rabinovitsj. The board recommends voting "FOR" both nominees for a three-year term.
• Proposal 2 (Accounting Firm Ratification): Shareholders vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
  • Financial Detail: The total fees paid to E&Y for 2025 were $958,373, down slightly from $949,550 in 2024.
• Committee Composition: Three specialized committees operate:
  • Audit Committee: Chaired by Ms. McGinnis. Responsible for reviewing financial statements and internal controls.
  • Compensation Committee: Chaired by Mr. Rabinovitsj. Responsible for reviewing and approving executive compensation.
  • Nominating & Corporate Governance Committee: Chaired by Mr. van Houten. Responsible for identifying and evaluating director candidates.

⚠️ Policies and Commitments

Absci has formalized several policies to promote compliance, ethical behavior, and transparency, which is crucial for any publicly traded company.

• Insider Trading Policy: The policy strictly prohibits Insiders (directors, officers, employees) from certain actions, including using company stock as collateral for loans or engaging in short sales.
• Compensation Recovery Policy: This policy allows the company to recover erroneously awarded incentive-based compensation if a material noncompliance with financial reporting is required.
• Code of Conduct: All employees, officers, and directors are required to review and sign an acknowledgment of the Code of Business Conduct and Ethics.

🚀 What's Next: Future Goals and Dates

The company set clear, high-stakes milestones for the immediate future.

• 2026 Priorities:
  • Presenting proof-of-concept data for ABS-201 in A.A. (HEADLINE) in the second half of 2026.
  • Initiating a global Phase 2 trial for ABS-201 in Endometriosis in Q4 2026.
  • Continuing development of Origin-1 against internal pipeline targets.
• Key Dates:
  • Annual Meeting: June 4, 2026.
  • Proxy Materials Mailed: On or about April 22, 2026.
  • Voting Deadline: Instructions must be received by June 3, 2026, for mail/phone voting.

📞 Contacts and Resources

For assistance, the company provides specific contact lines and mailing addresses.

• Principal Executive Offices: Absci Corporation, 18105 SE Mill Plain Blvd, Vancouver, WA 98683.
• Annual Meeting Support:
  • Technical Difficulty: (844) 986-0822 (U.S.) or (303) 562-9302 (International).
• Submitting Proposals: Shareholder proposals should be addressed to the Corporate Secretary at the main office, or emailed to [email protected].

---

🧠 The Analogy

Think of Absci's AI development as building a highly sophisticated, self-teaching factory (Origin-1) in the woods. Instead of relying on old, predictable supply routes, they use the AI to design entirely new, unconventional blueprints for medicines. The Proxy Statement is the company handing out a detailed map to the shareholders: on one hand, they show off the dazzling, potentially life-changing new products (ABS-201) that have already passed some early tests; and on the other hand, they show the complex local regulations (board rules, voting methods, etc.) that must be followed to ensure the entire operation runs smoothly and legally.

🧩 Final Takeaway

Absci is at a critical inflection point, rapidly advancing its lead candidate, ABS-201, across two major indications with impressive speed and cost efficiency. However, the company’s immediate future success hinges on the clinical proof-of-concept data expected in the second half of 2026.